Efficacy and safety of sapropterin before and during pregnancy: final analysis of the Kuvan® Adult Maternal Paediatric European Registry (KAMPER) maternal and Phenylketonuria Developmental Outcomes and Safety (PKUDOS) PKU-MOMs sub-registries
Infants born to mothers with phenylketonuria (PKU) may develop congenital abnormalities because of elevated phenylalanine (Phe) levels in the mother during pregnancy. Maintenance of blood Phe levels between 120 and 360 μmol/L reduces risks of birth defects. Sapropterin dihydrochloride helps maintain...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
July 2024
|
| In: |
Journal of inherited metabolic disease
Year: 2024, Volume: 47, Issue: 4, Pages: 636-650 |
| ISSN: | 1573-2665 |
| DOI: | 10.1002/jimd.12724 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1002/jimd.12724 Verlag, lizenzpflichtig, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/jimd.12724 
|
| Author Notes: | François Feillet, Can Ficicioglu, Florian B. Lagler, Nicola Longo, Ania C. Muntau, Alberto Burlina, Friedrich K. Trefz, Francjan J. van Spronsen, Jean-Baptiste Arnoux, Kristin Lindstrom, Joshua Lilienstein, Gillian E. Clague, Richard Rowell, Barbara K. Burton, on behalf of the KAMPER and PKUDOS investigators |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 189920105X | ||
| 003 | DE-627 | ||
| 005 | 20241205164016.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240820s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jimd.12724 |2 doi | |
| 035 | |a (DE-627)189920105X | ||
| 035 | |a (DE-599)KXP189920105X | ||
| 035 | |a (OCoLC)1475308556 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Feillet, François |e VerfasserIn |0 (DE-588)1339564785 |0 (DE-627)1899201491 |4 aut | |
| 245 | 1 | 0 | |a Efficacy and safety of sapropterin before and during pregnancy |b final analysis of the Kuvan® Adult Maternal Paediatric European Registry (KAMPER) maternal and Phenylketonuria Developmental Outcomes and Safety (PKUDOS) PKU-MOMs sub-registries |c François Feillet, Can Ficicioglu, Florian B. Lagler, Nicola Longo, Ania C. Muntau, Alberto Burlina, Friedrich K. Trefz, Francjan J. van Spronsen, Jean-Baptiste Arnoux, Kristin Lindstrom, Joshua Lilienstein, Gillian E. Clague, Richard Rowell, Barbara K. Burton, on behalf of the KAMPER and PKUDOS investigators |
| 264 | 1 | |c July 2024 | |
| 300 | |b Illustrationen | ||
| 300 | |a 15 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Erstveröffentlichung: 03 March 2024 | ||
| 500 | |a Gesehen am 20.08.2024 | ||
| 520 | |a Infants born to mothers with phenylketonuria (PKU) may develop congenital abnormalities because of elevated phenylalanine (Phe) levels in the mother during pregnancy. Maintenance of blood Phe levels between 120 and 360 μmol/L reduces risks of birth defects. Sapropterin dihydrochloride helps maintain blood Phe control, but there is limited evidence on its risk-benefit ratio when used during pregnancy. Data from the maternal sub-registries—KAMPER (NCT01016392) and PKUDOS (NCT00778206; PKU-MOMs sub-registry)—were collected to assess the long-term safety and efficacy of sapropterin in pregnant women in a real-life setting. Pregnancy and infant outcomes, and the safety of sapropterin were assessed. Final data from 79 pregnancies in 57 women with PKU are reported. Sapropterin dose was fairly constant before and during pregnancy, with blood Phe levels maintained in the recommended target range during the majority (82%) of pregnancies. Most pregnancies were carried to term, and the majority of liveborn infants were reported as ‘normal’ at birth. Few adverse and serious adverse events were considered related to sapropterin, with these occurring in participants with high blood Phe levels. This report represents the largest population of pregnant women with PKU exposed to sapropterin. Results demonstrate that exposure to sapropterin during pregnancy was well-tolerated and facilitated maintenance of blood Phe levels within the target range, resulting in normal delivery. This critical real-world data may facilitate physicians and patients to make informed treatment decisions about using sapropterin in pregnant women with PKU and in women of childbearing age with PKU who are responsive to sapropterin. | ||
| 650 | 4 | |a BH4 | |
| 650 | 4 | |a maternal PKU | |
| 650 | 4 | |a PKU | |
| 650 | 4 | |a pregnancy | |
| 650 | 4 | |a registry | |
| 650 | 4 | |a sapropterin | |
| 700 | 1 | |a Ficicioglu, Can |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lagler, Florian B. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Longo, Nicola |e VerfasserIn |4 aut | |
| 700 | 1 | |a Muntau, Ania C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Burlina, Alberto |e VerfasserIn |4 aut | |
| 700 | 1 | |a Trefz, Friedrich K. |d 1945- |e VerfasserIn |0 (DE-588)130846341 |0 (DE-627)506362019 |0 (DE-576)298373289 |4 aut | |
| 700 | 1 | |a van Spronsen, Francjan J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Arnoux, Jean-Baptiste |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lindstrom, Kristin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lilienstein, Joshua |e VerfasserIn |4 aut | |
| 700 | 1 | |a Clague, Gillian E. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rowell, Richard |e VerfasserIn |4 aut | |
| 700 | 1 | |a Burton, Barbara K. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of inherited metabolic disease |d Hoboken, NJ : Wiley, 1978 |g 47(2024), 4 vom: Juli, Seite 636-650 |h Online-Ressource |w (DE-627)320457753 |w (DE-600)2006875-X |w (DE-576)105704652 |x 1573-2665 |7 nnas |a Efficacy and safety of sapropterin before and during pregnancy final analysis of the Kuvan® Adult Maternal Paediatric European Registry (KAMPER) maternal and Phenylketonuria Developmental Outcomes and Safety (PKUDOS) PKU-MOMs sub-registries |
| 773 | 1 | 8 | |g volume:47 |g year:2024 |g number:4 |g month:07 |g pages:636-650 |g extent:15 |a Efficacy and safety of sapropterin before and during pregnancy final analysis of the Kuvan® Adult Maternal Paediatric European Registry (KAMPER) maternal and Phenylketonuria Developmental Outcomes and Safety (PKUDOS) PKU-MOMs sub-registries |
| 856 | 4 | 0 | |u https://doi.org/10.1002/jimd.12724 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/abs/10.1002/jimd.12724 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20240820 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 130846341 |a Trefz, Friedrich K. |m 130846341:Trefz, Friedrich K. |d 50000 |e 50000PT130846341 |k 0/50000/ |p 7 | ||
| 999 | |a KXP-PPN189920105X |e 456922752X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedKey":"2024","dateIssuedDisp":"July 2024"}],"note":["Erstveröffentlichung: 03 March 2024","Gesehen am 20.08.2024"],"physDesc":[{"noteIll":"Illustrationen","extent":"15 S."}],"relHost":[{"origin":[{"dateIssuedDisp":"1978-","publisherPlace":"Hoboken, NJ ; Dordrecht [u.a.] ; Dordrecht [u.a.]","publisher":"Wiley ; Kluwer ; Springer Science + Business Media B.V","dateIssuedKey":"1978"}],"language":["eng"],"disp":"Efficacy and safety of sapropterin before and during pregnancy final analysis of the Kuvan® Adult Maternal Paediatric European Registry (KAMPER) maternal and Phenylketonuria Developmental Outcomes and Safety (PKUDOS) PKU-MOMs sub-registriesJournal of inherited metabolic disease","physDesc":[{"extent":"Online-Ressource"}],"note":["Gesehen am 11.03.20","Ungezählte Beil.: Suppl"],"pubHistory":["1.1978 -"],"id":{"doi":["10.1002/(ISSN)1573-2665"],"zdb":["2006875-X"],"eki":["320457753"],"issn":["1573-2665"]},"recId":"320457753","titleAlt":[{"title":"JIMD"}],"title":[{"title":"Journal of inherited metabolic disease","subtitle":"JIMD ; official journal of the Society for the Study of Inborn Errors of Metabolism","title_sort":"Journal of inherited metabolic disease"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"part":{"year":"2024","pages":"636-650","issue":"4","volume":"47","extent":"15","text":"47(2024), 4 vom: Juli, Seite 636-650"}}],"language":["eng"],"id":{"doi":["10.1002/jimd.12724"],"eki":["189920105X"]},"recId":"189920105X","name":{"displayForm":["François Feillet, Can Ficicioglu, Florian B. Lagler, Nicola Longo, Ania C. Muntau, Alberto Burlina, Friedrich K. Trefz, Francjan J. van Spronsen, Jean-Baptiste Arnoux, Kristin Lindstrom, Joshua Lilienstein, Gillian E. Clague, Richard Rowell, Barbara K. Burton, on behalf of the KAMPER and PKUDOS investigators"]},"type":{"media":"Online-Ressource","bibl":"article-journal"},"person":[{"role":"aut","given":"François","roleDisplay":"VerfasserIn","display":"Feillet, François","family":"Feillet"},{"family":"Ficicioglu","display":"Ficicioglu, Can","roleDisplay":"VerfasserIn","given":"Can","role":"aut"},{"role":"aut","family":"Lagler","given":"Florian B.","roleDisplay":"VerfasserIn","display":"Lagler, Florian B."},{"role":"aut","roleDisplay":"VerfasserIn","given":"Nicola","display":"Longo, Nicola","family":"Longo"},{"role":"aut","family":"Muntau","roleDisplay":"VerfasserIn","given":"Ania C.","display":"Muntau, Ania C."},{"family":"Burlina","display":"Burlina, Alberto","roleDisplay":"VerfasserIn","given":"Alberto","role":"aut"},{"role":"aut","family":"Trefz","roleDisplay":"VerfasserIn","given":"Friedrich K.","display":"Trefz, Friedrich K."},{"role":"aut","family":"van Spronsen","roleDisplay":"VerfasserIn","display":"van Spronsen, Francjan J.","given":"Francjan J."},{"role":"aut","family":"Arnoux","roleDisplay":"VerfasserIn","display":"Arnoux, Jean-Baptiste","given":"Jean-Baptiste"},{"family":"Lindstrom","display":"Lindstrom, Kristin","roleDisplay":"VerfasserIn","given":"Kristin","role":"aut"},{"family":"Lilienstein","display":"Lilienstein, Joshua","roleDisplay":"VerfasserIn","given":"Joshua","role":"aut"},{"roleDisplay":"VerfasserIn","given":"Gillian E.","display":"Clague, Gillian E.","family":"Clague","role":"aut"},{"role":"aut","given":"Richard","roleDisplay":"VerfasserIn","display":"Rowell, Richard","family":"Rowell"},{"role":"aut","family":"Burton","roleDisplay":"VerfasserIn","given":"Barbara K.","display":"Burton, Barbara K."}],"title":[{"subtitle":"final analysis of the Kuvan® Adult Maternal Paediatric European Registry (KAMPER) maternal and Phenylketonuria Developmental Outcomes and Safety (PKUDOS) PKU-MOMs sub-registries","title":"Efficacy and safety of sapropterin before and during pregnancy","title_sort":"Efficacy and safety of sapropterin before and during pregnancy"}]} | ||
| SRT | |a FEILLETFRAEFFICACYAN2024 | ||